These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 29419569)

  • 1. Brief Report: Statin Effects on Myocardial Fibrosis Markers in People Living With HIV.
    deFilippi C; Christenson R; Joyce J; Park EA; Wu A; Fitch KV; Looby SE; Lu MT; Hoffmann U; Grinspoon SK; Lo J
    J Acquir Immune Defic Syndr; 2018 May; 78(1):105-110. PubMed ID: 29419569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GDF-15, Galectin 3, Soluble ST2, and Risk of Mortality and Cardiovascular Events in CKD.
    Tuegel C; Katz R; Alam M; Bhat Z; Bellovich K; de Boer I; Brosius F; Gadegbeku C; Gipson D; Hawkins J; Himmelfarb J; Ju W; Kestenbaum B; Kretzler M; Robinson-Cohen C; Steigerwalt S; Bansal N
    Am J Kidney Dis; 2018 Oct; 72(4):519-528. PubMed ID: 29866459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of the biomarkers soluble ST2, galectin-3 and growth-differentiation factor-15 with heart failure and other non-cardiac diseases.
    Mueller T; Leitner I; Egger M; Haltmayer M; Dieplinger B
    Clin Chim Acta; 2015 May; 445():155-60. PubMed ID: 25850080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of statin therapy on coronary artery plaque volume and high-risk plaque morphology in HIV-infected patients with subclinical atherosclerosis: a randomised, double-blind, placebo-controlled trial.
    Lo J; Lu MT; Ihenachor EJ; Wei J; Looby SE; Fitch KV; Oh J; Zimmerman CO; Hwang J; Abbara S; Plutzky J; Robbins G; Tawakol A; Hoffmann U; Grinspoon SK
    Lancet HIV; 2015 Feb; 2(2):e52-63. PubMed ID: 26424461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin 6, galectin 3, growth differentiation factor 15, and soluble ST2 for mortality prediction in critically ill patients.
    Dieplinger B; Egger M; Leitner I; Firlinger F; Poelz W; Lenz K; Haltmayer M; Mueller T
    J Crit Care; 2016 Aug; 34():38-45. PubMed ID: 27288608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Galectin-3, GDF-15, and sST2 for the assessment of disease severity and therapy response in patients suffering from inoperable chronic thromboembolic pulmonary hypertension.
    Kriechbaum SD; Wiedenroth CB; Peters K; Barde MA; Ajnwojner R; Wolter JS; Haas M; Roller FC; Guth S; Rieth AJ; Rolf A; Hamm CW; Mayer E; Keller T; Liebetrau C
    Biomarkers; 2020 Nov; 25(7):578-586. PubMed ID: 32901511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multimarker multi-time point-based risk stratification strategy in acute heart failure: results from the RELAX-AHF trial.
    Demissei BG; Cotter G; Prescott MF; Felker GM; Filippatos G; Greenberg BH; Pang PS; Ponikowski P; Severin TM; Wang Y; Qian M; Teerlink JR; Metra M; Davison BA; Voors AA
    Eur J Heart Fail; 2017 Aug; 19(8):1001-1010. PubMed ID: 28133908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of Novel Cardiovascular Biomarkers in Patients With Pulmonary Hypertension (PH).
    Mirna M; Rohm I; Jirak P; Wernly B; Bäz L; Paar V; Kretzschmar D; Hoppe UC; Schulze PC; Lichtenauer M; Jung C; Franz M
    Heart Lung Circ; 2020 Mar; 29(3):337-344. PubMed ID: 31327702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relations of circulating GDF-15, soluble ST2, and troponin-I concentrations with vascular function in the community: The Framingham Heart Study.
    Andersson C; Enserro D; Sullivan L; Wang TJ; Januzzi JL; Benjamin EJ; Vita JA; Hamburg NM; Larson MG; Mitchell GF; Vasan RS
    Atherosclerosis; 2016 May; 248():245-51. PubMed ID: 26972631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subclinical myocyte injury, fibrosis and strain in relationship to coronary plaque in asymptomatic HIV-infected individuals.
    Fitch KV; DeFilippi C; Christenson R; Srinivasa S; Lee H; Lo J; Lu MT; Wong K; Petrow E; Sanchez L; Looby SE; Hoffmann U; Zanni M; Grinspoon SK
    AIDS; 2016 Sep; 30(14):2205-14. PubMed ID: 27314177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum oxidized low-density lipoprotein decreases in response to statin therapy and relates independently to reductions in coronary plaque in patients with HIV.
    Nou E; Lu MT; Looby SE; Fitch KV; Kim EA; Lee H; Hoffmann U; Grinspoon SK; Lo J
    AIDS; 2016 Feb; 30(4):583-90. PubMed ID: 26558731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The usefulness of sST2 and galectin-3 as novel biomarkers for better risk stratification in hypertrophic cardiomyopathy.
    Gawor M; Śpiewak M; Janas J; Kożuch K; Wróbel A; Mazurkiewicz Ł; Baranowski R; Marczak M; Grzybowski J
    Kardiol Pol; 2017; 75(10):997-1004. PubMed ID: 28612913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel mediators of statin effects on plaque in HIV: a proteomics approach.
    deFilippi C; Lo J; Christenson R; Grundberg I; Stone L; Zanni MV; Lee H; Grinspoon SK
    AIDS; 2018 Apr; 32(7):867-876. PubMed ID: 29369166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multibiomarker analysis in patients with acute myocardial infarction.
    Schernthaner C; Lichtenauer M; Wernly B; Paar V; Pistulli R; Rohm I; Jung C; Figulla HR; Yilmaz A; Cadamuro J; Haschke-Becher E; Pernow J; Schulze PC; Hoppe UC; Kretzschmar D
    Eur J Clin Invest; 2017 Sep; 47(9):638-648. PubMed ID: 28683166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum suppression of tumorigenicity 2 level is an independent predictor of all-cause mortality in HIV-infected patients.
    Thiébaut R; Hue S; Le Marec F; Lelièvre JD; Dupon M; Foucat E; Lazaro E; Dabis F; Duffau P; Wittkop L; Surenaud M; Pellegrin I; Lacabaratz C; Bonnet F; Lévy Y;
    AIDS; 2017 Nov; 31(17):2355-2365. PubMed ID: 29068834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Galectin-3 and sST2 in prediction of left ventricular ejection fraction after myocardial infarction.
    van der Velde AR; Lexis CP; Meijers WC; van der Horst IC; Lipsic E; Dokter MM; van Veldhuisen DJ; van der Harst P; de Boer RA
    Clin Chim Acta; 2016 Jan; 452():50-7. PubMed ID: 26528636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Interleukin-33/ST2 Pathway Is Expressed in the Failing Human Heart and Associated with Pro-fibrotic Remodeling of the Myocardium.
    Tseng CCS; Huibers MMH; van Kuik J; de Weger RA; Vink A; de Jonge N
    J Cardiovasc Transl Res; 2018 Feb; 11(1):15-21. PubMed ID: 29285671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased Plasma Concentrations of Soluble ST2 Independently Predict Mortality but not Cardiovascular Events in Stable Coronary Heart Disease Patients: 13-Year Follow-up of the KAROLA Study.
    Pfetsch V; Sanin V; Jaensch A; Dallmeier D; Mons U; Brenner H; Koenig W; Rothenbacher D
    Cardiovasc Drugs Ther; 2017 Apr; 31(2):167-177. PubMed ID: 28283847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The plasma levels of soluble ST2 as a marker of gut mucosal damage in early HIV infection.
    Mehraj V; Jenabian MA; Ponte R; Lebouché B; Costiniuk C; Thomas R; Baril JG; LeBlanc R; Cox J; Tremblay C; Routy JP;
    AIDS; 2016 Jun; 30(10):1617-27. PubMed ID: 27045377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic Value of Serial Measurements of Soluble Suppression of Tumorigenicity 2 and Galectin-3 in Ambulatory Patients With Chronic Heart Failure.
    Miller WL; Saenger AK; Grill DE; Slusser JP; Bayes-Genis A; Jaffe AS
    J Card Fail; 2016 Apr; 22(4):249-55. PubMed ID: 26277907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.